Table 2. Patient characteristics and biopsy outcomes according to glycemic control of DM.
| Variables | DM− | DM+GC | DM+PC | P-value |
| No. Patient | 1,030 | 238 | 100 | |
| Mean Age (range) | 66.7 (30–91) | 66.0 (34–86) | 67.8 (47–83) | 0.210 |
| Median PSA (ng/ml, range) | 7.2 (1.4–3081.0) | 6.0 (1.0–412.0) | 6.1 (1.2–42.1) | 0.207 |
| Median PSAD (ng/ml2, range) | 0.18 (0.03–13.32) | 0.15 (0.03–1.37) | 0.14 (0.04–0.72) | 0.037 |
| No. abnormal DRE finding (%) | 128 (12.4%) | 27 (11.3%) | 21 (21.0%) | 0.031 |
| Mean prostate volume (ml, range) | 45.0 (9–262) | 44.5 (14–126) | 45.5 (18–151) | 0.949 |
| Mean HbA1c (range) | - | 5.7 (4.4–6.4) | 7.4 (6.5–11.3) | <0.001 |
| No. overall Pca (%) | 301 (29.2%) | 48 (20.2%) | 44 (44.0%) | <0.001 |
| No. high-grade Pca (GS ≥7) (%) | 211 (20.5%) | 30 (12.6%) | 22 (22.0%) | 0.016 |
| GS 7 | 106 (10.3%) | 15 (6.3%) | 10 (10.0%) | |
| GS 3+4 | 61 (5.9%) | 8 (3.4%) | 7 (7.0%) | |
| GS 4+3 | 45 (4.4%) | 7 (2.9%) | 3 (3.0%) | |
| GS 8 | 57 (5.5%) | 8 (3.4%) | 8 (8..0%) | |
| GS 9 | 14 (1.4%) | 1 (0.4%) | 3 (3.0%) | |
| GS 10 | 11 (1.1%) | 1 (0.4%) | 0 (0%) |
DM, diabetes mellitus, DM−, no DM; DM+GC, DM with good glycemic control, HbA1c <6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥6.5%; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; DRE, digital rectal examination; Pca, prostate cancer; GS, Gleason Score.